Instil Bio, Inc.
NASDAQ:TILBiotechnology
+$0.01 today
- Market cap
- $50.53M
- Beta
- 1.91
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$6.99
Volume 0.02M
Average 0.03M
TIL Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Instil Bio, Inc.NASDAQ: TIL
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $985K fell 71.8% year over year, behind the -61.9% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 38.7% from the prior quarter. Over 3 fiscal years it compounded at -34.1% a year.
Context
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -71.8% toward the trailing-twelve-month pace of -61.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 8.69M USD
- Year-over-year change
- -49.6%
- 4-year CAGR
- -24.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.69M | -49.6% |
| FY2024 | 2024-12-31 | 17.26M | -5.0% |
| FY2023 | 2023-12-31 | 18.17M | -40.3% |
| FY2022 | 2022-12-31 | 30.44M | +16.2% |
| FY2021 | 2021-12-31 | 26.2M | — |
Stock-Based Compensation vs competitors
How TIL compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -61.9% is the 7th highest of 9, against a peer median of -27.0%.
- Over three fiscal years its annual growth of -34.1% compares with a peer median of +0.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.58M USD | -41.5% | +5.1% | — | |
| LTM Mar 2026 | $14.24M USD | -76.6% | -23.8% | — | |
| LTM Mar 2026 | $12.55M USD | -55.6% | -11.3% | 8.0% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $9.87M USD | -8.9% | +0.8% | 138.2% |
| LTM Mar 2026 | $7.69M USD | -12.5% | +2.7% | 768.9% | |
| LTM Mar 2026 | CA$6.75M CAD | +101.1% | +21.4% | — | |
| LTM Mar 2026 | $6.18M USD | -61.9% | -34.1% | — | |
| LTM Mar 2026 | $5.11M USD | +30.3% | -5.3% | 68.1% | |
| LTM Mar 2026 | €2.48M EUR | -152.9% | — | 8455.2% | |
| Peer median (excluding TIL) | — | -27.0% | +0.8% | 138.2% | |
Competitors are the stored peer set for TIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (156.79M) | (223.18M) | (156.09M) | (74.14M) | (71.37M) |
| Depreciation & Amortization | 2.75M | 5.99M | 4.76M | 3.61M | 534K |
| Deferred Income Tax | 710K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 26.2M | 30.44M | 18.17M | 17.26M | 8.69M |
| Change in Working Capital | 4.36M | (9.57M) | (9.02M) | (12.61M) | (560K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | (3.4M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.86M | (1.81M) | (1.13M) | (556K) | 116K |
| Other Working Capital | 499K | (7.76M) | (7.89M) | (12.05M) | 2.72M |
| Other Non-Cash Items | 636K | 16.15M | 60.15M | 10.18M | 26.09M |
| Operating Cash Flow | (122.14M) | (180.16M) | (82.03M) | (55.7M) | (36.62M) |
| Capital Expenditures | (57.83M) | (84.59M) | (20.66M) | (10M) | 0 |
| Acquisitions (Net) | 0 | 1.17M | 0 | 0 | 432K |
| Purchases of Investments | (1.11B) | (666.22M) | (301.47M) | (135.6M) | (100.86M) |
| Sales of Investments | 691M | 865.35M | 361.7M | 198.71M | 135.9M |
| Other Investing Activities | 0 | (1.17M) | 1.56M | 866K | 0 |
| Investing Cash Flow | (474.4M) | 114.54M | 41.13M | 53.97M | 25.48M |
| Debt Repayment | 0 | 70.34M | 8.08M | 2.76M | 6.61M |
| Common Stock Issued | 339.02M | 1.55M | 0 | 0 | 853K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.69M | 0 | 0 | (1.01M) | (172K) |
| Financing Cash Flow | 393.16M | 71.89M | 8.08M | 1.76M | 7.29M |
| Effect of Forex Changes | (304K) | (637K) | (201K) | (94K) | 20K |
| Net Change in Cash | (203.67M) | 5.63M | (33.02M) | (61K) | (3.83M) |
| Free Cash Flow | (179.97M) | (264.75M) | (102.69M) | (65.7M) | (36.62M) |
Instil Bio, Inc.
NASDAQ:TIL
Intrinsic Alpha fair value
Locked
Current Price
$7.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.